Bold opening: Blood lipids may hold the key to understanding early primary biliary cholangitis (PBC), and new findings suggest a distinctive lipid signature that could transform how this chronic autoimmune liver disease is diagnosed and treated.
A collaborative study from multiple Polish medical centers examined plasma sphingolipid profiles in 45 individuals with early-stage PBC who were receiving standard ursodeoxycholic acid therapy, comparing them to samples from 30 healthy controls. Utilizing state-of-the-art ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS), researchers identified a pattern of sphingolipid alterations that appear closely linked to inflammation, immune dysregulation, and initial fibrotic activity in the liver.
Sphingolipid changes associated with early PBC
The most striking finding was a general drop in total sphingolipids among PBC patients, with a pronounced decline in several phosphorylated lipids, notably sphingosine-1-phosphate (S1P) and sphinganine-1-phosphate (SPA1P). These lipids are known to influence immune signaling and vascular function. Importantly, their reduced levels correlated with portal hemodynamic abnormalities detected by Doppler ultrasound, suggesting a potential role in the circulatory disturbances frequently observed in cholestatic liver diseases.
Ceramides show a contrasting pattern in PBC
In contrast, levels of C18:1-ceramide were higher in the PBC group and tended to associate with increased liver stiffness, a surrogate marker of evolving fibrosis. At the same time, very-long-chain ceramides—lipids that may perform protective metabolic functions—were decreased.
Links between lipids and inflammatory markers emerged as well. Notably, sphingosine levels correlated positively with interleukin-6, a cytokine involved in chronic inflammation and autoimmune activity. These associations bolster the view that sphingolipids are active participants in the immune dysregulation and tissue remodeling that accompany PBC, not merely bystanders.
Implications and future directions
The authors describe these observations as a selective, disease-specific pattern of sphingolipid alterations in early PBC. While larger and longitudinal studies are needed to validate these findings, the data imply that certain sphingolipids could serve as biomarkers of disease activity or even as therapeutic targets. This work opens a new avenue for the management of cholestatic liver diseases by focusing on lipid signaling pathways.
Reference
Rogalska M et al. Altered sphingolipid profile in primary biliary cholangitis: associations with fibrosis and inflammation. Sci Rep. 2025; 15:42502.
Author:
This article is provided under the Creative Commons Attribution-Non Commercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/).
